ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company specializing in therapeutics for neurodegenerative diseases, has announced its participation in the BTIG Virtual Biotechnology Conference 2024. The company's representatives, Neil Warma (interim CEO) and Dr. Larry Altstiel (Chief Medical Officer), will engage in a fireside chat on August 6, 2024, at 12:00 p.m. ET.
ProMIS Neurosciences focuses on developing treatments targeting toxic misfolded proteins, which are associated with various neurodegenerative conditions. The fireside chat will be available via live webcast to conference attendees, providing an opportunity for investors and industry professionals to gain insights into the company's progress and future plans.
ProMIS Neurosciences Inc. (Nasdaq: PMN), un azienda biotecnologica specializzata in terapie per le malattie neurodegenerative, ha annunciato la sua partecipazione alla Conferenza Virtuale di Biotecnologia BTIG 2024. I rappresentanti dell'azienda, Neil Warma (CEO ad interim) e Dr. Larry Altstiel (Direttore Medico), parteciperanno a un talk informale il 6 agosto 2024, alle 12:00 ET.
ProMIS Neurosciences si concentra sullo sviluppo di trattamenti mirati a proteine tossiche malripiegate, associate a diverse condizioni neurodegenerative. Il talk informale sarà disponibile tramite webcast in diretta per i partecipanti alla conferenza, offrendo un'opportunità agli investitori e ai professionisti del settore di ottenere informazioni sui progressi e futuri progetti dell'azienda.
ProMIS Neurosciences Inc. (Nasdaq: PMN), una empresa biotecnológica especializada en terapias para enfermedades neurodegenerativas, ha anunciado su participación en la Conferencia Virtual de Biotecnología BTIG 2024. Los representantes de la compañía, Neil Warma (CEO interino) y Dr. Larry Altstiel (Director Médico), participarán en una charla informal el 6 de agosto de 2024, a las 12:00 p.m. ET.
ProMIS Neurosciences se enfoca en desarrollar tratamientos que apunten a proteínas tóxicas mal plegadas, asociadas con diversas condiciones neurodegenerativas. La charla informal estará disponible a través de transmisión en vivo para los asistentes a la conferencia, brindando una oportunidad a inversores y profesionales del sector para obtener información sobre el progreso y los planes futuros de la compañía.
ProMIS Neurosciences Inc. (Nasdaq: PMN)는 신경퇴행성 질환에 대한 치료법을 전문으로 하는 바이오텍 기업입니다. 이 회사는 BTIG 가상 생명공학 컨퍼런스 2024에 참여한다고 발표했습니다. 회사의 대표인 Neil Warma (임시 CEO)와 Dr. Larry Altstiel (최고 의료 책임자)는 2024년 8월 6일 오후 12시 ET에 편안한 대화를 진행할 예정입니다.
ProMIS Neurosciences는 다양한 신경퇴행성 질환과 관련된 독성의 잘못 접힌 단백질을 표적하는 치료법 개발에 초점을 맞추고 있습니다. 이번 편안한 대화는 참가자들에게 라이브 웹캐스트를 통해 제공되어, 투자자와 업계 전문가들이 회사의 진행 상황과 향후 계획에 대한 통찰을 얻을 수 있는 기회를 제공합니다.
ProMIS Neurosciences Inc. (Nasdaq: PMN), une entreprise biopharmaceutique spécialisée dans les thérapeutiques pour les maladies neurodégénératives, a annoncé sa participation à la Conférence Virtuelle de Biotechnologie BTIG 2024. Les représentants de l'entreprise, Neil Warma (PDG par intérim) et Dr. Larry Altstiel (Directeur Médical), prendront part à une discussion informelle le 6 août 2024 à 12h00 ET.
ProMIS Neurosciences se concentre sur le développement de traitements ciblant les protéines mal repliées toxiques, qui sont associées à diverses conditions neurodégénératives. La discussion informelle sera disponible via un webdiffusion en direct pour les participants à la conférence, offrant ainsi une occasion aux investisseurs et aux professionnels de l'industrie d'obtenir des informations sur les progrès et les futurs projets de l'entreprise.
ProMIS Neurosciences Inc. (Nasdaq: PMN), ein Biotechnologieunternehmen, das sich auf Therapeutika für neurodegenerative Erkrankungen spezialisiert hat, hat seine Teilnahme an der BTIG Virtuellen Biotechnologiekonferenz 2024 angekündigt. Die Vertreter des Unternehmens, Neil Warma (Interim-CEO) und Dr. Larry Altstiel (Chefmedizinischer Direktor), werden am 6. August 2024 um 12:00 Uhr ET an einem Feuerplatzgespräch teilnehmen.
ProMIS Neurosciences konzentriert sich auf die Entwicklung von Behandlungen, die auf toxische falsch gefaltete Proteine abzielen, die mit verschiedenen neurodegenerativen Erkrankungen assoziiert sind. Das Feuerplatzgespräch wird den Teilnehmern der Konferenz über Live-Webcast zur Verfügung stehen, was Investoren und Branchenfachleuten die Möglichkeit bietet, Einblicke in den Fortschritt und die zukünftigen Pläne des Unternehmens zu erhalten.
- None.
- None.
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that Neil Warma, interim Chief Executive Officer of ProMIS Neurosciences and Larry Altstiel, M.D., Ph.D., Chief Medical Officer of ProMIS Neurosciences, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 6, 2024 at 12:00 p.m. ET.
A live webcast of the fireside chat will be available to conference participants.
About ProMIS Neurosciences Inc.
ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company’s proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS has offices in Toronto, Ontario and Cambridge, Massachusetts.
For further information:
Visit us at www.promisneurosciences.com
Please submit media inquiries to info@promisneurosciences.com.
For Investor Relations, please contact:
Precision AQ
Anne Marie Fields, Managing Director
annemarie.fields@precisionaq.com
Tel. 212-362-1200
FAQ
When is ProMIS Neurosciences (PMN) participating in the BTIG Virtual Biotechnology Conference 2024?
Who will represent ProMIS Neurosciences (PMN) at the BTIG Virtual Biotechnology Conference 2024?
What is the focus of ProMIS Neurosciences (PMN) in biotechnology?
Will there be a live webcast of ProMIS Neurosciences' (PMN) fireside chat at the BTIG conference?
